Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenues of $30,500,000, representing a 38% year-over-year increase [8][18] - Net income for the quarter was $5,100,000, compared to a net loss of $500,000 in Q1 2024 [21] - Cash generated from operations was $7,900,000, a significant increase from $300,000 in the same period last year [22] - The company ended the quarter with $55,600,000 in cash and no debt, maintaining strong liquidity [21] Business Line Data and Key Metrics Changes - E-commerce sales grew by 31% year-over-year, contributing significantly to revenue growth [9][18] - The food grade and pharmaceutical grade Niagen ingredient business saw a 95% increase, reaching $8,000,000 [9][18] - Gross margin improved to 63.4%, up from 60.7% a year ago, driven by a favorable product mix and cost savings [18] Market Data and Key Metrics Changes - The demand for NAD-boosting products is surging, with increasing consumer awareness of Niagen as a trusted solution [12][14] - The company aims to expand its presence in clinics, targeting 1,000 clinics by the end of 2025, with a potential addressable market of 2,000 to 3,000 clinics [42] Company Strategy and Development Direction - The company is focused on reinforcing Niagen as the leading NAD-boosting solution, aligning its brand with its mission of promoting healthy aging [15][16] - The pharmaceutical application of nicotinamide riboside (NR) is a key strategic initiative, with ongoing studies and FDA dialogues [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum across e-commerce and ingredient businesses, raising the full-year growth outlook to 20% to 25% [22][23] - The company is committed to operational discipline and efficiency, with a focus on long-term profitability [26] Other Important Information - The company announced a new composition of matter patent granted in March, broadening its patent portfolio [11] - Management highlighted the importance of maintaining integrity and scientific rigor in the NAD supplement market [13][14] Q&A Session Summary Question: What are the emerging tailwinds for NIAGEN IV product adoption? - Management noted significant interest from clinics and physicians, with 600 clinics currently offering NIAGEN IV and expectations for increased sales [28][32] Question: Are there new promotional strategies for e-commerce? - Management indicated a focus on profitability and efficiency, with plans to increase presence on platforms like TikTok and engage with influencers [35][37] Question: What is the potential market for NIAGEN plus? - Management aims to onboard 1,000 clinics by year-end, with a larger addressable market identified [42] Question: What is the status of the injectable NIAGEN plus? - Management confirmed that an at-home version is in development, expected to be available by Q4 2025 [72][73] Question: What is the status of the FDA discussions regarding ataxia telangiectasia? - Active discussions are ongoing with the FDA, with a pre-IND submission made and feedback received [90][91]